Stock of the Day for August 9, 2024

Eli Lilly and Company Stock Report

Eli Lilly and Company
LLY 90-day performance NYSE:LLY Eli Lilly and Company
Current Price
$754.90
-1.38 (-0.18%)
(As of 09/12/2025 03:59 PM ET)
30 Day Performance
7.61%
  
 
90 Day Performance
-4.64%
  
  
1 Year Performance
-18.28%
  
  
Market Capitalization
$714.48B
P/E Ratio
49.34
Dividend Yield
0.79%

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical firm headquartered in Indianapolis, Indiana, that discovers, develops, manufactures and markets human pharmaceuticals in a wide range of therapeutic areas. The company’s core focus includes neuroscience, endocrinology, oncology, immunology and cardiovascular disease. Through a vertically integrated research and development model, Eli Lilly advances novel small molecules and biologics from early research through commercialization, serving both adult and pediatric patient populations.

Founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War, the company has grown from a regional drug manufacturer into one of the world’s leading innovators in life sciences. Early achievements included the introduction of insulin for diabetes management in the 1920s and penicillin production during World War II. Over more than a century of operation, Eli Lilly has been credited with pioneering contributions to psychopharmacology, hormone therapies and targeted cancer treatments.

Key marketed products span several disease areas: in diabetes care, it offers rapid- and long-acting insulins as well as injectable GLP-1 receptor agonists; in oncology, its portfolio includes small-molecule kinase inhibitors and immuno-oncology antibodies; and in immunology, the company develops therapies for inflammatory conditions such as rheumatoid arthritis and psoriasis. Complementing these marketed drugs, Lilly maintains an active pipeline with candidates advancing across multiple phases of clinical trials.

Eli Lilly serves patients in more than 120 countries through a combination of direct operations and partnerships. The company emphasizes global manufacturing and supply chain resilience, with major production sites in North America, Europe and Asia. Under the leadership of President and Chief Executive Officer David A. Ricks, Lilly continues to invest heavily in research collaborations, digital health solutions and initiatives to expand access to medicines worldwide.

LLY Company Calendar

AUG. 7, 2025
Last Earnings
AUG. 15, 2025
Ex-Dividend for 9/10 Dividend
SEP. 10, 2025
Dividend Payable
SEP. 15, 2025
Today
OCT. 29, 2025
Next Earnings (Estimated)
DEC. 31, 2025
Fiscal Year End

Recent Eli Lilly and Company News

3 Monster Stocks to Hold for the Next 5 Years
Capital Market Strategies LLC Cuts Stock Position in Eli Lilly and Company $LLY
InvesTrust Sells 4,313 Shares of Eli Lilly and Company $LLY
Crumly & Associates Inc. Reduces Stake in Eli Lilly and Company $LLY
Jacobs & Co. CA Has $23.86 Million Stock Holdings in Eli Lilly and Company $LLY
Wesbanco Bank Inc. Raises Holdings in Eli Lilly and Company $LLY
Neville Rodie & Shaw Inc. Purchases 897 Shares of Eli Lilly and Company $LLY
Kings Path Partners LLC Makes New Investment in Eli Lilly and Company $LLY
This report was written by MarketBeat.com on September 15, 2025. This report first appeared on MarketBeat.com.